Introduction
Recent preclinical and clinical studies have revealed that stroke and many neurological disorders share a common pathogenic triad which includes: (i) vascular damage, (ii) neuronal injury and/or neurodegeneration, and (iii) the neuroinflammatory response (reviewed in [1] [2] [3] [4] ). Moreover, it has became increasingly recognized that, in addition to neurons, different cell types comprising the neurovascular unit -vascular cells (endothelium, pericytes, vascular smooth muscle cells) and glia (astrocytes, microglia, oligodendroglia) -can contribute to brain damage after an acute ischemic stroke [1, 2] and/or during a chronic neurodegenerative process [3] [4] [5] [6] .
Despite years of research and pioneering clinical work, stroke remains a major public health concern. Current research in stroke has been directed at developing rational approaches for neuronal protection [1] , advancing the existing acute reperfusion therapies [7, 8] , advancing diverse devices and strategies for mechanical revascularization [9] , and developing treatments aimed to promote regeneration of brain tissue damaged by ischemia [10, 11] . Although the different concepts of neuroprotection are based on a sound scientific principle and data from preclinical studies, none of neuroprotectants has been successfully translated into a stroke therapy in humans [12] . By analyzing methodological quality and efficacy of 1026 stroke drugs tested in over 8500 experiments in 3500 publications, O'Collins et al. determined that only five drugs met the STAIR (Stroke Therapy Academic Industry Roundtable) criteria for drug development for stroke [13] . We have also learned that adherence to the STAIR criteria does not guarantee success in clinical application in humans.
A recent failure of the Stroke-Acute Ischemic NXY Treatment (SAINT) II trial evaluating the free-radical scavenger NXY-059 in acute ischemic stroke [14] has prompted discussions about the quality of preclinical and clinical stroke studies [12] . Most experts generally agree that there is no evidence to suggest a biological barrier to translating stroke research from animals to humans, but the quality of preclinical research has been identified as a potential problem. It has been also argued that clinical trials could have underestimated the sample size needed to show an effect based on conventional outcome scales [15] . Moreover, computed tomography and magnetic resonance imaging of infarct volumes fail to show the expected correlation with clinical outcomes [16] [17] [18] rendering these imaging biomarkers unacceptable to regulatory agencies as validated end-points sufficient to grant approval of a neuroprotectant drug.
As a solution to these problems, it has been recommended that, even before testing in animal models, a candidate drug should have a clearly defined molecular mechanism of action, a valid molecular target, an acceptable toxicity profile, appropriate pharmacokinetics and pharmacodynamics, and a demonstrated ability to cross the BBB [19] . As a subsequent step, a rigorous testing of neuroprotectants in animal models should follow a roadmap established by the STAIR committee [20, 21] .
Preclinical and clinical studies have clearly shown that so-called single-action-single-target agents are unlikely to
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